Plate Nº 10 · recorded October 10, 2026
Biology & EvolutionReported finding
Treatment Timing Can Decide Therapy Success, Yeast Study Finds
Yeast experiments at the Max Planck Zentrum für Physik und Medizin show that even small shifts in treatment timing can determine whether resistant cells stay contained or spread during therapy.
By Elena Vasquez3 min read687 words
In brief
- The study was published in Nature Ecology & Evolution in 2026 (DOI: 10.1038/s41559-026-03178-z).
- Even small changes in treatment timing can determine the success of therapy, the experiments showed.
- Optimal treatment efficacy sits at the boundary between two distinct outcome classes controlled by spatial resource dynamics.
- Researchers used genetically modified yeast cells and a 'Real-To-Sim-To-Real' approach pairing experiments with computer simulations.
- The findings are fundamental and cannot yet be applied to patient treatment, according to group leader Dr. Jona Kayser.
Small changes in the timing of treatment cycles can decide whether a therapy succeeds or fails, according to a new study published in Nature Ecology & Evolution in 2026. Researchers at the Max-Planck-Zentrum für Physik und Medizin (MPZPM) demonstrated in yeast experiments that physical processes in dense cell populations set a narrow "sweet spot" of optimal treatment timing — and that missing it by even a little can let resistant cells spread.
The finding matters because treatment resistance is one of the central obstacles in modern cancer therapy and antibiotic treatment. Tumors and microbial infections that survive the first rounds of therapy often come back harder to kill. The new work suggests that when doctors administer a drug can be as important as how much of it they give.
Why dense cell colonies behave unexpectedly
Solid tumors and microbial biofilms share a defining physical feature: their cells are packed tightly together. Nutrients, oxygen and other resources essential for growth are plentiful at the outer edge of the colony but grow scarce toward the center. This gradient, not genetics alone, regulates how fast individual cells can grow.
That has a protective side effect. Resistant cells that arise deep inside a dense population find themselves starved of resources, so they grow slowly and spread only gradually. The colony's own architecture acts as a natural brake on dangerous mutants.
Treatment upends this balance — sometimes with serious consequences for the course of therapy. Killing off cells changes the local environment, which in turn changes how the surviving cells grow and compete. An interdisciplinary team led by Dr. Jona Kayser, head of the Emmy Noether Research Group "Cellular Evolution" at MPZPM, set out to understand exactly how this coupling between environment and growth influences the emergence of resistance.
How the researchers tested it
The team used what they call a "Real-To-Sim-To-Real" approach. They first ran therapy-mimicking experiments with genetically modified yeast cells, then used the results to build digital twins — computer models that replicate the behavior of the real system. Strategies optimized in the simulation went back to the laboratory bench for testing.
"We use a 'Real-To-Sim-To-Real' approach. In this approach, therapy-mimicking experiments with genetically modified yeast cells serve as the basis for digital twins. The therapeutic strategies optimized on the computer are subsequently tested in experiments," said Nico Appold, one of the two lead authors of the study.
This loop between experiment and simulation revealed a striking pattern. The physical coupling of environmental and growth dynamics split treatment outcomes into two distinct classes — broadly, regimes where resistance stays contained and regimes where it escapes. The optimal treatment window sits precisely at the boundary between the two.
"Our results show that even small changes in treatment timing can determine the success of therapy," said Timon Citak, the study's other lead author.
What this could mean for future therapies
The study's central insight is that treatment does not only act on cells directly. It also reshapes their surroundings — nutrient gradients, crowding, and space to grow — and those environmental changes feed back on how the cell population evolves. For evolutionary therapeutic approaches, this means the overall size of a tumor may matter less than previously assumed, while how and where cells regrow during treatment breaks could become a key planning factor.
The researchers are careful to stress the limits of the work. The experiments involve yeast, a single-celled model organism, not human patients.
"Our findings are fundamental in nature and reveal underlying mechanisms. They cannot be applied to the treatment of patients yet, but in the long term, this physical understanding could be crucial to the success of future treatment strategies," Kayser said.
"In the next step, we want to investigate whether similar physical mechanisms also occur in more realistic model systems, such as three-dimensional tumor organoids," he added. Tumor organoids — miniature, lab-grown versions of tumors — would bring the research one step closer to clinical reality.
The study, by Nico Appold, Timon Citak, Kayser and colleagues, appears in Nature Ecology & Evolution (DOI: 10.1038/s41559-026-03178-z).
via Phys.org Biology (Source)
More from Elena Vasquez
Show full bio
Correspondent covering money, funding and market shifts around general science news at SciBeat.
254 articles
Nearby plates
- Inflammation Can Wake Up 'Sleeping' Cancer Cells Hidden in Bone
- Lung Cancers Evade KRAS Drugs by Switching Cell Type
- New Drug CS18 Reverses Cancer Treatment Resistance in Lab Tests
- Nanoparticles flag and destroy hidden glioblastoma cells in mice
- Cells That Cheat Death May Explain Healing and Cancer Relapse